Receptor tyrosine kinase targeting in glioblastoma: performance, limitations and future approaches

Oana Alexandru; Cristina Horescu; Ani-Simona Sevastre; Catalina Cioc; Carina Baloi; Alexandru Oprita; Anica Dricu

doi:10.5114/wo.2020.94726

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2020
vol. 24

Send email

Copy url:

abstract:

Review paper

Receptor tyrosine kinase targeting in glioblastoma: performance, limitations and future approaches

Oana Alexandru

¹

,

Cristina Horescu

²

,

Ani-Simona Sevastre

³

,

Catalina Elena Cioc

²

,

Carina Baloi

²

,

Alexandru Oprita

²

,

Anica Dricu

²

Department of Neurology, University of Medicine and Pharmacy of Craiova and Clinical Hospital of Neuropsychiatry Craiova, Craiova, Romania
Unit of Biochemistry, University of Medicine and Pharmacy of Craiova, Craiova, Romania
Unit of Pharmaceutical Technology, University of Medicine and Pharmacy of Craiova, Craiova, Romania

Contemp Oncol (Pozn) 2020; 24 (1): 55-66

DOI: https://doi.org/10.5114/wo.2020.94726

Online publish date: 2020/03/30

View full text Get citation

PlumX metrics:

From all central nervous system tumors, gliomas are the most common. Nowadays, researchers are looking for more efficient treatments for these tumors, as well as ways for early diagnosis. Receptor tyrosine kinases (RTKs) are major targets for oncology and the development of small-molecule RTK inhibitors has been proven successful in cancer treatment. Mutations or aberrant activation of the RTKs and their intracellular signaling pathways are linked to several malignant diseases, including glioblastoma. The progress in the understanding of malignant glioma evolution has led to RTK targeted therapies with high capacity to improve the therapeutic response while reducing toxicity. In this review, we present the most important RTKs (i.e. EGFR, IGFR, PDGFR and VEGFR) currently used for developing cancer therapeutics together with the potential of RTK-related drugs in glioblastoma treatment. Also, we focus on some therapeutic agents that are currently at different stages of research or even in clinical phases and proved to be suitable as re-purposing candidates for glioblastoma treatment.

keywords:

Receptor tyrosine kinase targeting in glioblastoma: performance, limitations and future approaches

Oana Alexandru 1 , Cristina Horescu 2 , Ani-Simona Sevastre 3 , Catalina Elena Cioc 2 , Carina Baloi 2 , Alexandru Oprita 2 , Anica Dricu 2

glioma, RTKs, targeted therapy

Oana Alexandru

¹

,

Cristina Horescu

²

,

Ani-Simona Sevastre

³

,

Catalina Elena Cioc

²

,

Carina Baloi

²

,

Alexandru Oprita

²

,

Anica Dricu

²